Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 22897848)

1.

Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.

Sander S, Calado DP, Srinivasan L, Köchert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R, Bullinger L, Rajewsky K.

Cancer Cell. 2012 Aug 14;22(2):167-79. doi: 10.1016/j.ccr.2012.06.012.

2.

The E-Id protein axis modulates the activities of the PI3K-AKT-mTORC1-Hif1a and c-myc/p19Arf pathways to suppress innate variant TFH cell development, thymocyte expansion, and lymphomagenesis.

Miyazaki M, Miyazaki K, Chen S, Chandra V, Wagatsuma K, Agata Y, Rodewald HR, Saito R, Chang AN, Varki N, Kawamoto H, Murre C.

Genes Dev. 2015 Feb 15;29(4):409-25. doi: 10.1101/gad.255331.114.

3.

Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis.

Sabò A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, Morelli MJ, Bora P, Doni M, Verrecchia A, Tonelli C, Fagà G, Bianchi V, Ronchi A, Low D, Müller H, Guccione E, Campaner S, Amati B.

Nature. 2014 Jul 24;511(7510):488-92. doi: 10.1038/nature13537. Epub 2014 Jul 9.

4.

Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer.

Cunningham JT, Moreno MV, Lodi A, Ronen SM, Ruggero D.

Cell. 2014 May 22;157(5):1088-103. doi: 10.1016/j.cell.2014.03.052. Erratum in: Cell. 2014 Jul 31;158(3):689.

5.

MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas.

Schneider C, Setty M, Holmes AB, Maute RL, Leslie CS, Mussolin L, Rosolen A, Dalla-Favera R, Basso K.

Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8185-90. doi: 10.1073/pnas.1322466111. Epub 2014 May 19.

6.

A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.

Berg T, Thoene S, Yap D, Wee T, Schoeler N, Rosten P, Lim E, Bilenky M, Mungall AJ, Oellerich T, Lee S, Lai CK, Umlandt P, Salmi A, Chang H, Yue L, Lai D, Cheng SW, Morin RD, Hirst M, Serve H, Marra MA, Morin GB, Gascoyne RD, Aparicio SA, Humphries RK.

Blood. 2014 Jun 19;123(25):3914-24. doi: 10.1182/blood-2012-12-473439. Epub 2014 May 6.

7.

Burkitt lymphoma and MYC: what else is new?

Said J, Lones M, Yea S.

Adv Anat Pathol. 2014 May;21(3):160-5. doi: 10.1097/PAP.0b013e3182a92cde. Review.

PMID:
24713985
8.

[Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases].

Zhou J, Xia C, Shen Q, Yin H, Zhang X, Shi Q, Zhou X, Ma J.

Zhonghua Bing Li Xue Za Zhi. 2014 Jan;43(1):8-14. Chinese.

PMID:
24713242
9.

Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.

Ferreira AC, Robaina MC, Rezende LM, Severino P, Klumb CE.

Ann Hematol. 2014 Jun;93(6):983-93. doi: 10.1007/s00277-014-2021-4. Epub 2014 Feb 28.

PMID:
24577510
10.

Oncogenic mechanisms in Burkitt lymphoma.

Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM.

Cold Spring Harb Perspect Med. 2014 Feb 1;4(2). pii: a014282. doi: 10.1101/cshperspect.a014282. Review.

PMID:
24492847
11.

Analysis of the IGHV region in Burkitt's lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis.

Baptista MJ, Calpe E, Fernandez E, Colomo L, Cardesa-Salzmann TM, Abrisqueta P, Bosch F, Crespo M.

Leuk Res. 2014 Apr;38(4):509-15. doi: 10.1016/j.leukres.2014.01.001. Epub 2014 Jan 13.

PMID:
24480549
12.

Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.

Spender LC, Inman GJ.

Cancer Manag Res. 2014 Jan 9;6:27-38. doi: 10.2147/CMAR.S37745. Review.

13.

A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.

Salaverria I, Martin-Guerrero I, Wagener R, Kreuz M, Kohler CW, Richter J, Pienkowska-Grela B, Adam P, Burkhardt B, Claviez A, Damm-Welk C, Drexler HG, Hummel M, Jaffe ES, Küppers R, Lefebvre C, Lisfeld J, Löffler M, Macleod RA, Nagel I, Oschlies I, Rosolowski M, Russell RB, Rymkiewicz G, Schindler D, Schlesner M, Scholtysik R, Schwaenen C, Spang R, Szczepanowski M, Trümper L, Vater I, Wessendorf S, Klapper W, Siebert R; Molecular Mechanisms in Malignant Lymphoma Network Project; Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group.

Blood. 2014 Feb 20;123(8):1187-98. doi: 10.1182/blood-2013-06-507996. Epub 2014 Jan 7.

14.

SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma.

Jeong SM, Lee A, Lee J, Haigis MC.

J Biol Chem. 2014 Feb 14;289(7):4135-44. doi: 10.1074/jbc.M113.525949. Epub 2013 Dec 24.

15.

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Küppers R, Lenze D, Ott G, Pott C, Richter J, Rosenwald A, Szczepanowski M, Schwaenen C, Stein H, Trautmann H, Wessendorf S, Trümper L, Loeffler M, Spang R, Kluin PM, Klapper W, Siebert R; Molecular Mechanisms in Malignant Lymphomas Network Project.

Haematologica. 2014 Apr;99(4):726-35. doi: 10.3324/haematol.2013.091827. Epub 2013 Oct 31.

16.

Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1.

Ramkumar C, Cui H, Kong Y, Jones SN, Gerstein RM, Zhang H.

Nat Commun. 2013;4:2598. doi: 10.1038/ncomms3598.

17.

Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis.

Cowling VH, Turner SA, Cole MD.

Oncogene. 2014 Jul 3;33(27):3519-27. doi: 10.1038/onc.2013.338. Epub 2013 Sep 9.

PMID:
24013231
18.

MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways.

Jin HY, Oda H, Lai M, Skalsky RL, Bethel K, Shepherd J, Kang SG, Liu WH, Sabouri-Ghomi M, Cullen BR, Rajewsky K, Xiao C.

EMBO J. 2013 Aug 28;32(17):2377-91. doi: 10.1038/emboj.2013.178. Epub 2013 Aug 6.

19.

Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.

Vettraino M, Manerba M, Govoni M, Di Stefano G.

Anticancer Drugs. 2013 Sep;24(8):862-70. doi: 10.1097/CAD.0b013e328363ae50.

PMID:
23797802
20.

Loss of connective tissue growth factor as an unfavorable prognosis factor activates miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in nasopharyngeal carcinoma.

Yu X, Zhen Y, Yang H, Wang H, Zhou Y, Wang E, Marincola FM, Mai C, Chen Y, Wei H, Song Y, Lyu X, Ye Y, Cai L, Wu Q, Zhao M, Hua S, Fu Q, Zhang Y, Yao K, Liu Z, Li X, Fang W.

Cell Death Dis. 2013 May 16;4:e634. doi: 10.1038/cddis.2013.153. Erratum in: Cell Death Dis. 2013;4:e672.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk